Ben Derman, Assistant Professor at University of Chicago, shared a post on X:
“Is your center allowing for BCMA CAR T-cell therapy in patients with myeloma on dialysis for renal failure?
We describe our early experience with ide-cel/cilta-cel in patients on dialysis. Bottom line:
- Don’t let ESKD be a barrier!
- Reducing fludarabine plus dialyzing each day afterward worked well
- Note: there may be a signal for increased risk of IEC-HS.“
More posts featuring Ben Derman.